Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Inderberg EM"" wg kryterium: Autor


Tytuł :
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Autorzy :
Aamdal E; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Akershus University Hospital, Lørenskog, Norway.
Inderberg EM; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway.
Ellingsen EB; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway.
Rasch W; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway.
Brunsvig PF; Department of Oncology, Oslo University Hospital, Oslo, Norway.
Aamdal S; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway.
Heintz KM; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Vodák D; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Nakken S; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Hovig E; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway.
Nyakas M; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Guren TK; Department of Oncology, Oslo University Hospital, Oslo, Norway.
Gaudernack G; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Ultimovacs Allmennaksjeselskap (ASA), Oslo, Norway.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 May 11; Vol. 12, pp. 663865. Date of Electronic Publication: 2021 May 11 (Print Publication: 2021).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Autorzy :
Dillard P; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway.
Köksal H; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway.
Maggadottir SM; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway.
Winge-Main A; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway.
Pollmann S; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway.
Menard M; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway.
Myhre MR; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway.
Mælandsmo GM; Department of Tumor Biology, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway.
Flørenes VA; Department of Pathology, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway.
Gaudernack G; Department of Cancer Immunology, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway.
Kvalheim G; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway.
Wälchli S; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway. Electronic address: .
Inderberg EM; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway. Electronic address: .
Pokaż więcej
Źródło :
Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2021 Mar 03; Vol. 29 (3), pp. 1199-1213. Date of Electronic Publication: 2020 Nov 17.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Combinatorial CAR design improves target restriction.
Autorzy :
Köksal H; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Dillard P; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Juzeniene A; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Kvalheim G; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; K.G. Jebsen Centre for B Cell Malignancies, University of Oslo, Oslo, Norway.
Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; K.G. Jebsen Centre for B Cell Malignancies, University of Oslo, Oslo, Norway.
Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Wälchli S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway. Electronic address: .
Pokaż więcej
Źródło :
The Journal of biological chemistry [J Biol Chem] 2020 Dec 03; Vol. 296, pp. 100116. Date of Electronic Publication: 2020 Dec 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Autorzy :
Brunsvig PF; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.
Guren TK; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.
Nyakas M; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.
Steinfeldt-Reisse CH; Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Rasch W; Ultimovacs ASA, Oslo, Norway.
Kyte JA; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.
Juul HV; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.
Aamdal S; Ultimovacs ASA, Oslo, Norway.
Gaudernack G; Ultimovacs ASA, Oslo, Norway.
Inderberg EM; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2020 Nov 26; Vol. 11, pp. 572172. Date of Electronic Publication: 2020 Nov 26 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy.
Autorzy :
Benard E; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Casey NP; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Inderberg EM; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Wälchli S; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Pokaż więcej
Źródło :
Scandinavian journal of immunology [Scand J Immunol] 2020 Oct; Vol. 92 (4), pp. e12917.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Carcinoma, Ovarian Epithelial/*immunology
Ovarian Neoplasms/*immunology
Receptors, Chimeric Antigen/*immunology
Tumor Microenvironment/*immunology
Animals ; Antigens, Neoplasm/immunology ; Carcinoma, Ovarian Epithelial/therapy ; Female ; Humans ; Immunotherapy, Adoptive/methods ; Ovarian Neoplasms/therapy ; Receptors, Chimeric Antigen/therapeutic use ; Tumor Escape/immunology
Czasopismo naukowe
Tytuł :
T cell receptor therapy against melanoma-Immunotherapy for the future?
Autorzy :
Winge-Main AK; Department of Cellular Therapy, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.; Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Wälchli S; Department of Cellular Therapy, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Inderberg EM; Department of Cellular Therapy, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Pokaż więcej
Źródło :
Scandinavian journal of immunology [Scand J Immunol] 2020 Oct; Vol. 92 (4), pp. e12927.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy/*methods
Melanoma/*immunology
Melanoma/*therapy
Receptors, Antigen, T-Cell/*immunology
Skin Neoplasms/*immunology
Skin Neoplasms/*therapy
Animals ; Humans
SCR Disease Name :
Melanoma, Cutaneous Malignant
Czasopismo naukowe
Tytuł :
Sympathetic improvement of cancer vaccine efficacy.
Autorzy :
Inderberg EM; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital , Oslo, Norway.
Wälchli S; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital , Oslo, Norway.
Pokaż więcej
Źródło :
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2020 Aug 02; Vol. 16 (8), pp. 1888-1890. Date of Electronic Publication: 2020 Jan 24.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Colorectal cysts as a validating tool for CAR therapy.
Autorzy :
Dillard P; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Lie M; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Baken E; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Lobert VH; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Benard E; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Köksal H; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Wälchli S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. .
Pokaż więcej
Źródło :
BMC biotechnology [BMC Biotechnol] 2020 Jun 01; Vol. 20 (1), pp. 30. Date of Electronic Publication: 2020 Jun 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Long-term surviving cancer patients as a source of therapeutic TCR.
Autorzy :
Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway. .
Wälchli S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2020 May; Vol. 69 (5), pp. 859-865. Date of Electronic Publication: 2020 Jan 08.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Cancer Survivors*
CD4-Positive T-Lymphocytes/*transplantation
Immunotherapy, Adoptive/*methods
Neoplasms/*therapy
Receptors, Antigen, T-Cell/*isolation & purification
CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; Cancer Vaccines/administration & dosage ; Clinical Trials as Topic ; Histocompatibility Antigens Class II/immunology ; Humans ; Immunotherapy, Adoptive/trends ; Neoplasms/blood ; Neoplasms/immunology ; Receptors, Antigen, T-Cell/immunology ; Receptors, Antigen, T-Cell/metabolism
Czasopismo naukowe
Tytuł :
Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients.
Autorzy :
Andersson Y; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Department of Oncology, Østfold Hospital Trust, Grålum, Norway.
Inderberg EM; Department of Cellular Therapy, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Kvalheim G; Department of Cellular Therapy, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Herud TM; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Engebraaten O; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway.
Flatmark K; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Gastroenterological Surgery, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Dueland S; Department of Oncology, Oslo University Hospital, Oslo, Norway.
Fodstad Ø; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Pokaż więcej
Źródło :
Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2020 Apr; Vol. 59 (4), pp. 404-409. Date of Electronic Publication: 2019 Dec 26.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Colorectal Neoplasms/*mortality
Cyclosporine/*therapeutic use
Epithelial Cell Adhesion Molecule/*antagonists & inhibitors
Immunoconjugates/*therapeutic use
Immunotoxins/*therapeutic use
Colorectal Neoplasms/immunology ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/therapy ; Epithelial Cell Adhesion Molecule/immunology ; Epithelial Cell Adhesion Molecule/metabolism ; Humans ; Immunosuppressive Agents/therapeutic use ; Neoplasm Metastasis ; Prognosis ; Survival Rate
Czasopismo naukowe
Tytuł :
Posttransplantation Lymphoproliferative Disease Treated by Retransplantation.
Autorzy :
Weum Abrahamsen I; Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Grønvold BC; Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
Mensali N; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
Mattsson J; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.
Gedde-Dahl T; Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Pokaż więcej
Źródło :
Case reports in immunology [Case Reports Immunol] 2020 Feb 25; Vol. 2020, pp. 9403123. Date of Electronic Publication: 2020 Feb 25 (Print Publication: 2020).
Typ publikacji :
Case Reports
Raport
Tytuł :
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.
Autorzy :
Mensali N; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Myhre MR; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Dillard P; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Pollmann S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Gaudernack G; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.; Faculty of Medicine, University of Oslo, 0316, Oslo, Norway.
Kvalheim G; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Wälchli S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway. .
Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2020 Jan; Vol. 69 (1), pp. 159-161.
Typ publikacji :
Journal Article; Published Erratum
Czasopismo naukowe
Tytuł :
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.
Autorzy :
Mensali N; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Myhre MR; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Dillard P; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Pollmann S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Gaudernack G; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.; Faculty of Medicine, University of Oslo, 0316, Oslo, Norway.
Kvalheim G; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.
Wälchli S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway. .
Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2019 Aug; Vol. 68 (8), pp. 1235-1243. Date of Electronic Publication: 2019 Jun 18.
Typ publikacji :
Journal Article
MeSH Terms :
Cancer Vaccines/*immunology
Colorectal Neoplasms/*therapy
Immunotherapy, Adoptive/*methods
Receptors, Chimeric Antigen/*metabolism
T-Lymphocytes/*immunology
Animals ; Colorectal Neoplasms/immunology ; Cross Reactions ; Cytotoxicity, Immunologic ; Electroporation ; HCT116 Cells ; Humans ; Mice ; Mice, SCID ; Neoplasms, Experimental ; RNA, Messenger/genetics ; Receptors, Chimeric Antigen/genetics ; T-Cell Antigen Receptor Specificity ; T-Lymphocytes/transplantation ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Chimeric antigen receptor preparation from hybridoma to T-cell expression.
Autorzy :
Köksal H; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo 0379, Norway.
Baken E; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo 0379, Norway.
Warren DJ; Department of Medical Biochemistry, Oslo University Hospital-Radiumhospitalet, Oslo 0379, Norway.
Løset GÅ; Department of Biosciences, University of Oslo, Oslo 0316, Norway.; Nextera AS, Oslo, Norway.
Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo 0379, Norway.
Wälchli S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo 0379, Norway.
Pokaż więcej
Źródło :
Antibody therapeutics [Antib Ther] 2019 May 31; Vol. 2 (2), pp. 56-63. Date of Electronic Publication: 2019 May 31 (Print Publication: 2019).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
Autorzy :
Köksal H; Division of Cancer Medicine, Department of Cellular Therapy, and.
Dillard P; Division of Cancer Medicine, Department of Cellular Therapy, and.
Josefsson SE; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
Maggadottir SM; Division of Cancer Medicine, Department of Cellular Therapy, and.
Pollmann S; Division of Cancer Medicine, Department of Cellular Therapy, and.
Fåne A; Division of Cancer Medicine, Department of Cellular Therapy, and.
Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
Beiske K; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Division of Cancer Medicine, Department of Pathology, and.
Huse K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
Kolstad A; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway; and.; KG Jebsen Centre for Cancer Immunotherapy, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
Holte H; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway; and.
Kvalheim G; Division of Cancer Medicine, Department of Cellular Therapy, and.
Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell Malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
Inderberg EM; Division of Cancer Medicine, Department of Cellular Therapy, and.
Wälchli S; Division of Cancer Medicine, Department of Cellular Therapy, and.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2019 Apr 23; Vol. 3 (8), pp. 1230-1243.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adoptive Transfer*
Lymphoma, B-Cell*/immunology
Lymphoma, B-Cell*/pathology
Lymphoma, B-Cell*/therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/immunology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Antigens, Neoplasm/*immunology
Receptors, Chimeric Antigen/*immunology
Tetraspanins/*immunology
Animals ; Antigens, CD19/immunology ; Humans ; Jurkat Cells ; K562 Cells ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy.
Autorzy :
Theodossiou TA; 1Department of Radiation Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway.
Ali M; 2Department of Immunology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway.
Grigalavicius M; 1Department of Radiation Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway.
Grallert B; 1Department of Radiation Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway.
Dillard P; 3Department of Cellular Therapy, Department of Oncology, Radium Hospital, Oslo University Hospital, Oslo, Norway.
Schink KO; 4Department of Molecular Cell Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway.
Olsen CE; 1Department of Radiation Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway.
Wälchli S; 3Department of Cellular Therapy, Department of Oncology, Radium Hospital, Oslo University Hospital, Oslo, Norway.
Inderberg EM; 3Department of Cellular Therapy, Department of Oncology, Radium Hospital, Oslo University Hospital, Oslo, Norway.
Kubin A; PLANTA Naturstoffe Vertriebs GmbH, A-1120 Wien, Austria.
Peng Q; 6Department of Pathology, Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway.
Berg K; 1Department of Radiation Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway.
Pokaż więcej
Źródło :
NPJ breast cancer [NPJ Breast Cancer] 2019 Apr 10; Vol. 5, pp. 13. Date of Electronic Publication: 2019 Apr 10 (Print Publication: 2019).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Treating osteosarcoma with CAR T cells.
Autorzy :
Köksal H; Laboratory of Translational Research & Immunomonitoring, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Müller E; Laboratory of Translational Research & Immunomonitoring, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Inderberg EM; Laboratory of Translational Research & Immunomonitoring, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Bruland Ø; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Wälchli S; Laboratory of Translational Research & Immunomonitoring, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway.
Pokaż więcej
Źródło :
Scandinavian journal of immunology [Scand J Immunol] 2019 Mar; Vol. 89 (3), pp. e12741. Date of Electronic Publication: 2019 Jan 15.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Bone Neoplasms/*therapy
Immunotherapy, Adoptive/*methods
Osteosarcoma/*therapy
Bone Neoplasms/immunology ; Bone Neoplasms/mortality ; Cancer-Associated Fibroblasts/physiology ; Gangliosides/antagonists & inhibitors ; Gelatinases/physiology ; Humans ; Membrane Proteins/physiology ; Osteosarcoma/immunology ; Osteosarcoma/mortality ; Receptor, ErbB-2/analysis ; Receptor, IGF Type 1/physiology ; Receptors, Interleukin-11/antagonists & inhibitors ; Serine Endopeptidases/physiology ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
NK cells specifically TCR-dressed to kill cancer cells.
Autorzy :
Mensali N; Department of Cellular Therapy, Department for Cancer Therapy, Oslo University Hospital Radiumhospitalet, Oslo 0379, Norway.
Dillard P; Department of Cellular Therapy, Department for Cancer Therapy, Oslo University Hospital Radiumhospitalet, Oslo 0379, Norway.
Hebeisen M; Centre Universitaire Hospitalier Vaudois, University of Lausanne, Lausanne 1011, Switzerland.
Lorenz S; Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo 0379, Norway.
Theodossiou T; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo 0379, Norway.
Myhre MR; Department of Cellular Therapy, Department for Cancer Therapy, Oslo University Hospital Radiumhospitalet, Oslo 0379, Norway.
Fåne A; Department of Cellular Therapy, Department for Cancer Therapy, Oslo University Hospital Radiumhospitalet, Oslo 0379, Norway.
Gaudernack G; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo 0379, Norway.
Kvalheim G; Department of Cellular Therapy, Department for Cancer Therapy, Oslo University Hospital Radiumhospitalet, Oslo 0379, Norway.
Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo 0379, Norway; Centre for Cancer Biomedicine, University of Oslo, Oslo 0316, Norway.
Inderberg EM; Department of Cellular Therapy, Department for Cancer Therapy, Oslo University Hospital Radiumhospitalet, Oslo 0379, Norway. Electronic address: .
Wälchli S; Department of Cellular Therapy, Department for Cancer Therapy, Oslo University Hospital Radiumhospitalet, Oslo 0379, Norway. Electronic address: .
Pokaż więcej
Źródło :
EBioMedicine [EBioMedicine] 2019 Feb; Vol. 40, pp. 106-117. Date of Electronic Publication: 2019 Jan 18.
Typ publikacji :
Journal Article
MeSH Terms :
Cytotoxicity, Immunologic*/genetics
Killer Cells, Natural/*immunology
Killer Cells, Natural/*metabolism
Neoplasms/*immunology
Neoplasms/*metabolism
Receptors, Antigen, T-Cell/*metabolism
Animals ; Biomarkers ; Cell Line, Tumor ; Cell Respiration ; Disease Models, Animal ; Energy Metabolism ; Gene Expression Profiling ; Humans ; Immunophenotyping ; Mice ; Mitochondria/metabolism ; Neoplasms/pathology ; Neoplasms/therapy ; Signal Transduction ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism ; Transcriptome ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity.
Autorzy :
Mensali N; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.; Department of Molecular Biosciences, University of Oslo, Oslo, Norway.
Grenov A; Department of Molecular Biosciences, University of Oslo, Oslo, Norway.; Centre for Immune Regulation, University of Oslo, Oslo, Norway.
Pati NB; Department of Molecular Biosciences, University of Oslo, Oslo, Norway.; Centre for Immune Regulation, University of Oslo, Oslo, Norway.
Dillard P; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Myhre MR; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Gaudernack G; Department of Cancer Immunology, Institute for cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Kvalheim G; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Bakke O; Department of Molecular Biosciences, University of Oslo, Oslo, Norway.; Centre for Immune Regulation, University of Oslo, Oslo, Norway.
Wälchli S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Pokaż więcej
Źródło :
Oncoimmunology [Oncoimmunology] 2019 Jan 11; Vol. 8 (3), pp. 1558663. Date of Electronic Publication: 2019 Jan 11 (Print Publication: 2019).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies